Zscaler pops 6% on reaffirmed revenue outlook and IBM security pact, but core risks remain unresolved

What happened

Zscaler shares jumped 6% to $230 after the company reaffirmed its prior revenue outlook and announced a security partnership with IBM, lifting peer cybersecurity stocks as well. The reaffirmation appears to be a reiteration rather than an upgrade, leaving the previously guided FY27 growth range of 16%-17% unchanged and failing to address concerns about organic net new ARR growth, which remained weak ex-Red Canary. The IBM pact could expand distribution or product integration, but no financial terms or revenue impact have been disclosed, making the announcement more strategic than immediately accretive. The master report's base case implied value of $155 and bull case of $185 both sit well below the current price, suggesting the market is now pricing in a more optimistic scenario than the fundamentals support. Given the unresolved sales leadership turnover, elevated capex, and lack of measurable AI monetization, the rally appears driven by sentiment rather than a material improvement in operating quality.

Implication

The reaffirmed outlook does not change the core thesis that Zscaler must prove organic growth reacceleration and cash-flow recovery before it deserves a premium multiple. At $230, the stock trades well above the report's bearish and base scenarios and even exceeds the bull case of $185, leaving little margin of safety. The IBM partnership may add distribution or technology benefits but lacks disclosed economics, so it should not be modeled as a near-term revenue driver. Key monitoring points remain unchanged: ex-Red Canary net new ARR, FY27 capex guidance, and any measurable AI security contribution. Until those metrics inflect positively, the prudent stance is to remain on the sidelines rather than elevate exposure based on a reaffirmed outlook.

Thesis delta

The investment thesis remains unchanged: Zscaler owns a real architectural moat, but the current price does not justify the risk of its execution gaps. This news does not invalidate the prior WAIT rating, but it increases the probability the stock will correct toward the $135-$155 range if the next two quarters fail to deliver organic reacceleration. The reaffirmed outlook and IBM pact may briefly support sentiment, but they do not resolve the sales disruption, capex pressure, or AI disclosure concerns that drove the master report's conservative value.